# Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

> **NCT05635357** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 16989 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Exemestane/Letrozole

## Key facts

- **NCT ID:** NCT05635357
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 16989 (ACTUAL)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635357, "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05635357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*